tirzepatide news october 2025 Medscape | The FDA approved Zepbound in December 2024 for the treatment of moderate-to-severe obstructive sleep apnea in patients with obesity after First raid on UK illegal

Today, I was proud to announce ServiceNows major investment in South Florida and welcome the opportunities it will create for Floridians. ServiceNow is a Silicon Valley AI software firm taking 200,000 sq

Conversely, estrogen therapy can affect glucose metabolism and insulin sensitivity, though effects vary based on formulation, dose, and route of administration

A drug can move a fluid biomarker in the apparently favourable direction and still fail the patient

have warned that increasingly popular weight-loss drugs like Ozempic may carry extra risks for people who need surgery

Expect it to peak around the second week post-procedure

The genetic test maps 49 peptide markers across 14 metabolic pathways, giving PlexusDx clinical insight into how your body responds to GLP-1 activation, GIP signaling, appetite-regulating circuits, and nutrient sensing